Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.
about
Methodological criticisms in the evaluation of Pneumococcal Conjugate Vaccine effectivenessPneumococcal serotype evolution in Western EuropePneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010Invasive pneumococcal isolates from Danish infants (0 - 90 Days) during the years 1943 to 2013Serotype replacement in disease after pneumococcal vaccinationThe status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern BrazilPediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in DenmarkIn vitro growth of pneumococcal isolates representing 23 different serotypes.Clonal expansion within pneumococcal serotype 6C after use of seven-valent vaccine.Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccinesInteraction of Vaccination and Reduction of Antibiotic Use Drives Unexpected Increase of Pneumococcal Meningitis.Population-based study of the association between asthma and pneumococcal disease in children.A Pneumococcal Carriage Study in Danish Pre-school Children before the Introduction of Pneumococcal Conjugate Vaccination.Characteristics of serogroup 20 S.pneumoniae isolates from Brazil.Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitisAnatomical site-specific contributions of pneumococcal virulence determinants.Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination.The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.Unusual exanthema combined with cerebral vasculitis in pneumococcal meningitis: a case report.Use of intracranial pressure monitoring in bacterial meningitis: a 10-year follow up on outcome and intracranial pressure versus head CT scans.Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.Dexamethasone treatment and prognostic factors in community-acquired bacterial meningitis: a Danish retrospective population-based cohort study.Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England.The risk of acquiring bacterial meningitis following surgery in Denmark, 1996-2009: a nationwide retrospective cohort study with emphasis on ear, nose and throat (ENT) and neurosurgery.
P2860
Q26770693-489AD94A-CB65-4331-9E1B-90F2FB86ECE4Q26782963-4663A506-793B-40B7-AD71-5FF821BCD048Q28359834-AA734FF8-1C73-4D28-B282-4EACE732DC0AQ34090191-77A46807-751E-4025-B73C-37105403363BQ34178363-5EA76512-44A5-40E2-95FE-FCBA02AFB6E2Q34254800-9C3C66DB-839F-4356-BEC5-053E9587F2CDQ34402444-177ECA9A-8AE0-435E-B740-BED17F760668Q34428419-F76CDDDC-22BF-4C3C-892D-94D51D16013BQ34568186-36FE0112-F06C-454D-8E2B-C81230E15828Q34736040-773A26F3-1E57-406B-B73C-E70FCBBA6D9AQ34749756-E4EB3A12-022E-4C2C-8640-975A9DDEDDCEQ34979620-332BA6E0-5EB6-4834-B3B4-33B4A22A15AEQ35716556-FE0A2D78-0DF1-4280-B062-7C02565D1925Q35867100-F0966849-A15B-4AB8-813C-EDAA9B205413Q35969430-B7B591D7-9FB6-4CFB-8029-F36C8A80BCD7Q36104413-C8D0BA60-E307-4E23-8B81-87C85A2D82E9Q36105725-133707B0-C890-4954-9970-D7E385509216Q37187296-A5900F84-A97B-41FA-A6CC-DB63121A346DQ37252799-8E81344F-979B-4045-970D-BB9611CC1B6BQ37844538-1222EE68-B9BD-44E3-BBDF-1BD4EB6A711FQ38080478-3D6CFA2C-4CB5-4627-A522-DBACA0222E09Q38419709-F81EE372-D073-4480-9A3E-65B65C6049E2Q38541919-8919711E-C183-4E25-AA5E-77E9D42646B4Q40386901-FD03A5B7-8451-4538-93B2-A810FEF28E71Q42205779-255F06B2-E31B-4186-902D-B60388A3D34CQ42223281-B95215D2-9A38-46AA-AAC2-D940C0C81B15Q45700280-C55A8E63-B114-4FCA-9E01-AF2786F0CB37Q50559493-2D3B4929-2C2A-4941-BAF2-40E7130EBF0B
P2860
Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Early effectiveness of heptava ...... ldhood Immunization Programme.
@en
Early effectiveness of heptava ...... ldhood Immunization Programme.
@nl
type
label
Early effectiveness of heptava ...... ldhood Immunization Programme.
@en
Early effectiveness of heptava ...... ldhood Immunization Programme.
@nl
prefLabel
Early effectiveness of heptava ...... ldhood Immunization Programme.
@en
Early effectiveness of heptava ...... ldhood Immunization Programme.
@nl
P2093
P50
P1433
P1476
Early effectiveness of heptava ...... ldhood Immunization Programme.
@en
P2093
Helle B Konradsen
Jens Jørgen Christensen
Michael Howitz
Palle Valentiner-Branth
Peter H Andersen
Zitta B Harboe
P304
P356
10.1016/J.VACCINE.2010.01.017
P407
P577
2010-01-20T00:00:00Z